Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure

Under continuous long-term treatment with abo- or onabotulinum toxin type A (BoNT/A), ~10 to 15% of patients with cervical dystonia (CD) will develop neutralizing antibodies and reduced responsiveness over an ~10-year treatment period. Among the botulinum neurotoxin type A preparations so far licens...

Full description

Bibliographic Details
Main Authors: Harald Hefter, Beyza Ürer, Raphaela Brauns, Dietmar Rosenthal, Sven G. Meuth, John-Ih Lee, Philipp Albrecht, Sara Samadzadeh
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Toxins
Subjects:
secondary treatment failure
incobotulinum toxin
neutralizing antibodies
low antigenicity
complex proteins
Online Access:https://www.mdpi.com/2072-6651/14/1/44

Internet

https://www.mdpi.com/2072-6651/14/1/44

Similar Items